MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
Covered in this story
Call it yourself
No calls on $SITC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Site Centers Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.